Rhythm Biosciences scores biomarker patents in Europe
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Rhythm Biosciences (ASX:RHY) has today announced that coverage of its granted European patent (EP2829881) has been confirmed in 13 jurisdictions: Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Sweden, Switzerland & Liechtenstein and the United Kingdom.
These countries can now be added to the list of Australia, China and Japan, who have already granted patents to RHY for its biomarker IP towards the diagnosis of colorectal cancer. The company also has patent applications pending in the US, Brazil and India.
The European patent claims cover RHY’s bio-technology geared at the diagnosis or detection of colorectal cancer via the assessment of the presence/ levels/ combinations of up to 31 biomarkers. In addition, the patents also relate to diagnostic kits comprising reagents used to undertake these assessments to ultimately assist in the accurate diagnosis of colorectal cancer. These patents won’t expire until July 14, 2031.
RHY’s Managing Director Dr Trevor Lockett commented on the news: “In balancing coverage against costs, Rhythm elected to file this pivotal patent family in countries with both significant populations and health care systems that are supportive of cancer preventive strategies.
RHY’s Chairman Shane Tanner added: “This is an important milestone for the company. With patent rights secured, Rhythm will now begin developing its commercialisation strategy for ColoSTAT in the UK and on the continent.”
To complete the company’s two-year research and development program, which remains the focus of its first round of funding, RHY will lodge applications for the European authorities for a CE mark for ColoSTAT. At the same time, in Australia it will look to apply to the TGA for listing of ColoSTAT on the Australian Register of Therapeutic Goods.
Once those stages of the R&D phase are finalised, RHY will then be able to sell its product in Europe, the UK and Australia through its intended region-specific plans for commercialisation.
As always, it should be noted that RHY is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
